All Stories

  1. Luteinizing Hormone-Releasing Hormone (LHRH)-Targeted Treatment in Ovarian Cancer
  2. Role of Hyaluronic Acid and Chondroitin Sulphate in Protecting Urinary Epithelium in Patients Operated for Differentiated Thyroid Cancer Undergoing Ablation Therapy with Iodine-131
  3. Morpho-Functional and Biochemical Characterization of Adrenal Masses in a Heterogeneous Cancer Population
  4. Validation of a Ready-to-Use Lyophilized Kit for Labeling IL2 with 68Ga: A New Avenue for Imaging Activated T-lymphocytes in Tumor Microenvironment
  5. [68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects
  6. EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0
  7. Intra and Inter-Rater Variability in the Interpretation of White Blood Cell Scintigraphy of Hip and Knee Prostheses
  8. Radiolabelled FGF-2 for Imaging Activated Fibroblasts in the Tumor Micro-Environment
  9. Peritoneal Carcinomatosis of Malignant Gynecological Origin: A Systematic Review of Imaging Assessment
  10. SARS-CoV-2 Affects Thyroid and Adrenal Glands: An 18F-FDG PET/CT Study
  11. Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates
  12. Imaging of Vascular Graft/Endograft Infection with Radiolabeled White Blood Cell Scan and [18F]FDG PET/CT
  13. Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use
  14. Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma
  15. A Systematic Review on Combined [18F]FDG and 68Ga-SSA PET/CT in Pulmonary Carcinoid
  16. Radioimmune Imaging of α4β7 Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease
  17. [18F]FDG Uptake in Non-Infected Endovascular Grafts: A Retrospective Study
  18. Evidence-based medicine: reviews and meta-analysis
  19. Present status and future trends in molecular imaging of lymphocytes
  20. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent
  21. Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update
  22. PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
  23. [18F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab
  24. Methods for Radiolabelling Nanoparticles: PET Use (Part 2)
  25. Methods for Radiolabelling Nanoparticles: SPECT Use (Part 1)
  26. Sjögren Syndrome: New Insights in the Pathogenesis and Role of Nuclear Medicine
  27. Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren’s Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications
  28. Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study
  29. Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series
  30. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation
  31. Basic statistics for nuclear medicine and radiology
  32. Gamma camera imaging of autoimmune diseases
  33. Gamma camera imaging of inflammatory bowel diseases
  34. Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR)
  35. Synthesis and Biodistribution of 99mTc-Labeled PLGA Nanoparticles by Microfluidic Technique
  36. An easy and practical guide for imaging infection/inflammation by [18F]FDG PET/CT
  37. In Vivo Imaging of Thyroid Cancer with 99mTc-TR1401 and 99mTc-TR1402: A Comparison Study in Dogs
  38. PET and SPECT Imaging of Tumor Micro-Environment: A Systematic Review of the Last 20 Years
  39. Extensive Histopathological Characterization of Inflamed Bowel in the Dextran Sulfate Sodium Mouse Model with Emphasis on Clinically Relevant Biomarkers and Targets for Drug Development
  40. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2
  41. In Vitro and In Vivo Evaluation of 99mTc-Polymyxin B for Specific Targeting of Gram-Bacteria
  42. Molecular Imaging of Autoimmune Diseases
  43. Handling of Doubtful WBC Scintigraphies in Patients with Suspected Prosthetic Joint Infections
  44. Imaging Bacteria with Radiolabelled Probes: Is It Feasible?
  45. Diabetic Foot Infections: The Diagnostic Challenges
  46. Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles
  47. Comparison of White Blood Cell Scintigraphy, FDG PET/CT and MRI in Suspected Diabetic Foot Infection: Results of a Large Retrospective Multicenter Study
  48. Imaging Modalities for the Diagnosis of Vascular Graft Infections: A Consensus Paper amongst Different Specialists
  49. RE: 99m Tc‐HMPAO‐leucocyte scintigraphy and [ 18 F]FDG‐PET/CT in infection
  50. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System
  51. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy
  52. Nuclear Medicine in Infectious Diseases
  53. Nuclear Medicine Imaging of Diabetic Foot Infections
  54. Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review
  55. Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults
  56. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
  57. State of the Art of Natural Killer Cell Imaging: A Systematic Review
  58. Letter to the Editor regarding Falstie-Jensen et al: “Labeled white blood cell/bone marrow single-photon emission computed tomography with computed tomography fails in diagnosing chronic periprosthetic shoulder joint infection”
  59. Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  60. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
  61. Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome
  62. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
  63. 99mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study
  64. Labelling and Clinical Performance of Human Leukocytes Labelled with 99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent
  65. The reconstructed natural history of type 1 diabetes mellitus
  66. Correction to: Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  67. PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review
  68. Comparison of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study
  69. Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  70. Consensus document for the diagnosis of peripheral bone infection in adults: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  71. Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells
  72. Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging
  73. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study
  74. Leukocyte Imaging of the Diabetic Foot
  75. Infection and inflammation imaging standardization: the EANM guidelines
  76. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline
  77. Radiolabelled nanoparticles for cancer diagnosis
  78. Recommendations on nuclear and multimodality imaging in IE and CIED infections
  79. Current Status of Molecular Imaging in Infections
  80. Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders
  81. Editorial: Molecular Imaging of Inflammation/Infection: The Future of Disease Management
  82. Molecular Imaging of Inflammatory Arthritis and Related Disorders
  83. New SPECT and PET Radiopharmaceuticals for Imaging Inflammatory Diseases: A Narrative Review
  84. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC
  85. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study
  86. Animal models for the study of inflammatory bowel diseases: a meta-analysis on modalities for imaging inflammatory lesions
  87. Hybrid fusion images in diagnostic and therapeutic procedures
  88. Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria
  89. Hybrid imaging of musculoskeletal infections
  90. In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy
  91. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the Americ...
  92. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET
  93. Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study.
  94. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast
  95. Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis
  96. Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory Diseases
  97. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype
  98. OUP accepted manuscript
  99. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis
  100. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis
  101. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany
  102. Corrigendum
  103. Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review
  104. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: a pilot study
  105. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)
  106. In vivo imaging of microorganisms
  107. Isolation and 111In–Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model
  108. Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors
  109. Comment on: “Diagnosis of Periprosthetic Joint Infection: The Role of Nuclear Medicine May Be Overestimated” by Claudio Diaz-Ledezma, Courtney Lamberton, Paul Lichtstein and Javad Parvizi
  110. 99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis
  111. In Vivo Imaging of Natural Killer Cell Trafficking in Tumors
  112. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
  113. Somatostatin Receptor Scintigraphy-Spect
  114. The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis
  115. Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
  116. Somatostatin Analogues
  117. Detection of Insulitis By Pancreatic Scintigraphy With99mTc-Labelled-IL2 and MRI in Patients With LADA (Action LADA 10)
  118. Imaging Infection and Inflammation
  119. In VivoEvaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis
  120. Imaging in dermal filler diagnostics: MRI how and why
  121. 99mTc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer
  122. Infection and inflammation imaging
  123. Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
  124. Comment on Aksoy et al.: FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection
  125. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery
  126. Reply to comment by Koranda: 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections—the choice of reference tissue for a semiquantitative analysis
  127. Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study
  128. Nuclear Medicine Imaging Modalities: Bone Scintigraphy, PET-CT, SPECT-CT
  129. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
  130. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections
  131. Diagnostic Imaging of Infections and Inflammatory Diseases
  132. Nuclear Medicine Imaging of Infections: Techniques, Acquisition Protocols and Interpretation Criteria
  133. Nuclear Medicine Imaging of Inflammatory Diseases
  134. Nuclear Medicine Imaging of Tuberculosis and Human Immunodeficiency Virus
  135. High Sensitive Thyroglobulin Assay on Thyroxine Therapy: Can it Avoid Stimulation Test in Low and High Risk Differentiated Thyroid Carcinoma Patients?
  136. Biological Therapies for Rheumatoid Arthritis: Progress to Date
  137. EANM/SNMMI Guideline for 18F-FDG Use in Inflammation and Infection
  138. Leukocyte and bacteria imaging in prosthetic joint infection
  139. About inflammation and infection
  140. The Use of18F-FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases
  141. Nuclear Medicine Imaging of Abdominal Infections and Inflammation
  142. Nuclear Medicine Imaging of Infections and Inflammation of Central Nervous System, Head and Neck Structures
  143. Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications
  144. Imaging of β-Cell Mass and Insulitis in Insulin-Dependent (Type 1) Diabetes Mellitus
  145. 11C-Hydroxytryptophan Uptake and Metabolism in Endocrine and Exocrine Pancreas
  146. The Role of Positron Emission Tomography in Inflammatory Bowel Disease
  147. Differences in the location and activity of intestinal Crohn’s disease lesions between adult and paediatric patients detected with MRI
  148. Added Value of 99mTc-HMPAO-Labeled Leukocyte SPECT/CT in the Characterization and Management of Patients with Infectious Endocarditis
  149. Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
  150. New frontiers of MRI in Crohn’s disease: motility imaging, diffusion-weighted imaging, perfusion MRI, MR spectroscopy, molecular imaging, and hybrid imaging (PET/MRI)
  151. Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis
  152. N-(4-18F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes
  153. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement?
  154. 99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients
  155. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques
  156. Can Sequential 18F-FDG PET/CT Replace WBC Imaging in the Diabetic Foot?
  157. Time for radiobiology in the nuclear medicine community
  158. In vivo biodistribution of stem cells using molecular nuclear medicine imaging
  159. 99mTc-besilesomab (Scintimun®) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells
  160. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections
  161. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide
  162. Synthesis and Evaluation of 99mTc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression
  163. FDG-PET/CT in infections: the imaging method of choice?
  164. Molecular Imaging of Inflammation/Infection: Nuclear Medicine and Optical Imaging Agents and Methods
  165. Erratum to: Guidelines for the labelling of leucocytes with 99mTc-HMPAO
  166. Erratum to: Guidelines for the labelling of leucocytes with 111In-oxine
  167. Molecular imaging in atherosclerosis
  168. Guidelines for the labelling of leucocytes with 111In-oxine
  169. Guidelines for the labelling of leucocytes with 99mTc-HMPAO
  170. Imaging of cell trafficking in Crohn's disease
  171. Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes
  172. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies
  173. Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes
  174. Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes
  175. Peptide receptor therapies in neuroendocrine tumors
  176. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients
  177. Long-term survival of endodontically treated, maxillary anterior teeth restored with either tapered or parallel-sided glass-fiber posts and full-ceramic crown coverage
  178. The Contribution Of Nuclear Medicine In The Diagnosis Of Bone Metastases
  179. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor  
  180. Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3
  181. Receptor Binding Ligands to Image Infection
  182. Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
  183. Decontamination of Root Canals with the Gallium-Aluminum-Arsenide Laser: Anin VitroStudy
  184. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study
  185. Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck
  186. Studying the Metabolic Activity of Red Bone Marrow by Means of FDG-PET: The Need for a Standardization
  187. Can we produce an image of bacteria with radiopharmaceuticals?
  188. Prognostic Value of CD25 Expression on Lymphocytes and Tumor Cells in Squamous-Cell Carcinoma of the Head and Neck
  189. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy
  190. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma
  191. Radiopharmaceuticals for imaging chronic lymphocytic inflammation
  192. Diagnosis of Vascular Prosthesis Infection: PET or SPECT?
  193. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma
  194. ANNEXIN V DETECTION OF LIPOPOLYSACCHARIDE-INDUCED CARDIAC APOPTOSIS
  195. Yeasts and filamentous fungi in bottled mineral water and tap water from municipal supplies
  196. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis
  197. Nuclear medicine imaging of bone infections
  198. Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis
  199. Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes
  200. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques
  201. Inflammatory bowel diseases: clinical update of practical guidelines
  202. Nuclear medicine imaging of inflammatory/infective disorders of the abdomen
  203. Small animal imaging by single photon emission using pinhole and coded aperture collimation
  204. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with 99mTc‐infliximab
  205. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy
  206. Biological evaluation of a polyvinyl siloxane impression material
  207. CT60 Single Nucleotide Polymorphisms of the Cytotoxic T-Lymphocyte–Associated Antigen-4 Gene Region is Associated with Graves' Disease in an Italian Population
  208. High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma
  209. The 17th International IRIST Congress Proceedings
  210. Scientific production and impact of nuclear medicine in Europe: how do we publish?
  211. 99mTc-EDDA/HYNIC-TOC in the Management of Medullary Thyroid Carcinoma
  212. Radiolabeled Annexin-V for Monitoring Treatment Response in Oncology
  213. Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003
  214. Radioiodinated Recombinant Human TSH: A Novel Radiopharmaceutical for Thyroid Cancer Metastases Detection
  215. The Proceedings of the 16th IRIST (International Research Group on Immunoscintigraphy and Therapy) Congress
  216. FDG-PET in infectious and inflammatory disease
  217. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract
  218. Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer
  219. False-Negative Tc-99m MIBI Scintigraphy in Histopathologically Proved Recurrent High-Grade Oligodendroglioma
  220. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases
  221. 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease
  222. Novel PET and SPECT radioligands for visualization of diseased regulatory pathways in breast carcinoma
  223. Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice
  224. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine
  225. Inflammatory Bowel Diseases: The Use of Radiolabelled Cytokines for In Vivo Evaluation of Inflammatory Activity
  226. Nuclear Medicine in the Management of Inflammatory and Infectious Diseases
  227. EDITORIAL
  228. Radiolabelled cytokines for imaging chronic inflammation
  229. Discordant Findings Between Tc-99m HMPAO Mixed Leukocytes and Tc-99m–Labeled Monoclonal Antibody Fragments (via LeukoScan) in a Patient with Pulmonary Aspergillosis
  230. Peptide Receptor Imaging
  231. Nuclear Medicine Imaging For Prediction or Early Assessment of Response to Chemotherapy in Patients Suffering From Breast Carcinoma
  232. Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging
  233. Biological Imaging for the Diagnosis of Inflammatory Conditions
  234. Assessment of Cancer-Associated Biomarkers by Positron Emission Tomography: Advances and Challenges
  235. Peptide radiopharmaceuticals for diagnosis and therapy
  236. Erratum to: Peptide radiopharmaceuticals for diagnosis and therapy
  237. Editorial
  238. THE DEVELOPING ROLE OF CYTOKINES FOR IMAGING INFLAMMATION AND INFECTION
  239. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet
  240. Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor
  241. CTLA-4 and HLA gene susceptibility to thyroidassociated orbitopathy
  242. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma
  243. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI)
  244. Characterization of a New Form of Inherited Hypercholesterolemia
  245. In vivo imaging of insulitis in autoimmune diabetes
  246. Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes
  247. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse
  248. A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime
  249. CD95 ligand expression on alpha cells: protection or killing?
  250. Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes
  251. CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice
  252. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele
  253. 4.P.288 The metabolic basis of a new form of recessive hypercholesterolemia: The “FH-like” hypercholesterolemia
  254. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)
  255. The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the In vivo detection of mononuclear cell infiltrates in immune-mediated diseases
  256. Metformin Does Not Alter Diabetes Incidence in the NOD Mouse
  257. Radiopharmaceuticals for the study of 4 inflammatory processes
  258. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes
  259. Standardizing Experiments with NOD Mice
  260. Effect of metformin on liver insulin metabolism and regional blood flow
  261. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study)
  262. Usefulness of scintigraphy using 99mTc-EMPAO labelled granulocytes (PMN) as early indicator of postoperative asymptomatic recurrence in Crohn's disease (CD)
  263. New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2
  264. Nicotinamide vs Steroids in Recent-Onset Diabetes: Impact on 3-Cell Function
  265. Histological study of pancreatic beta-cell loss in relation to the insulitis process in the non-obese diabetic mouse
  266. Randomized Trial Comparing Nicotinamide and Nicotinamide Plus Cyclosporin in Recent Onset Insulin-dependent Diabetes (IMDIAB 1)
  267. A simple method for the evaluation of receptor binding capacity of modified cytokines
  268. The effect of a heparin analogue, ITF-5005, on diabetes incidence and insulitis in the non-obese diabetic mouse
  269. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse
  270. NOD mouse colonies around the world- recent facts and figures
  271. What future for therapeutic prevention of Type I (insulin-dependent) diabetes mellitus?
  272. A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies
  273. Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse
  274. Clinical remission in patients with IDDM and family history of NIDDM
  275. Raised temperature reduces the incidence of diabetes in the NOD mouse
  276. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type 1 (insulin-dependent) diabetes mellitus
  277. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice
  278. In vivo kinetics of 1231-labelled insulin
  279. Imaging of leukocytic infiltration in human cerebral infarcts.
  280. Labelling of lymphocytes with indium 111 oxine: Effect on cell surface phenotype and antibody-dependent cellular cytotoxicity